An investigational drug to treat acromegaly has been granted Orphan Drug designation by the Food and Drug Administration (FDA).

Acromegaly is primarily caused by a benign pituitary adenoma and is characterized by the enlargement of the hands and feet, facial changes, hypertension, diabetes mellitus, and cardiomyopathy. DP1038 (octreotide acetate; Dauntless Pharmaceuticals), a somatostatin analog, uses the patented Intravail intranasal absorption technology developed by Aegis Therapeutics, offering patients a non-injectable alternative to treat this condition. 

Related Articles

A Phase 1 clinical study of DP1038 demonstrated robust safety and pharmacodynamic data in healthy subjects.

For more information call (858) 999-3053 or visit